10-Year Trend Analysis of Medicare Payment in Stroke Inpatient Hospital Admission
Abstract Body: Background: The direct medical costs of stroke in the United States were $84.4 billion in 2012 and were projected to rise by 157% to $217.3 billion by 2030. However, the 10-year trend in inpatient stroke care costs under Medicare, as well as the Medicare payment variation across different states, has yet to be thoroughly investigated.
Methods: This is a retrospective analysis of the 2013 to 2022 Medicare Inpatient Hospitals - by Provider and Service Data that provides inpatient hospital charges by Medicare Severity Diagnosis Related Group (DRG) in stroke admission (DRG: 61-66). Percentage change in stroke admission cost adjusted for healthcare inflation between 2013-14 to 2021-22 weighted for the number in each stroke DRG was included in the analysis.
Results: Between 2013 and 2022, nationwide there were a total of 2,007,005 unique stroke-related inpatient hospital claims, resulting in Medicare payments totaling $21.07 billion from the Medicare Services. In 2013, the mean Medicare payment, weighted per stroke DRG for each stroke admission, was $9,486.08 (95% CI: $9,448.98–$9,523.18) nationwide. By 2022, after adjusting for healthcare inflation, the mean Medicare payment, weighted per stroke DRG, increased to $10,047.34 (95% CI: $9,994.39–$10,100.30) nationwide (Figure 1). At the state level, the 10-year analysis of Medicare payment for stroke admissions revealed a 33% decrease in payment costs in Vermont, while Maryland experienced the highest increase, with a 23% rise in Medicare payment costs (Figure 2).
Conclusion: Nationwide, the overall Medicare payment for stroke-related DRG costs has increased by over $560 in the past decade after adjusting for healthcare inflation and weighted per-stroke DRGs. However, at the state level, certain states have experienced a reduction in Medicare payments for stroke admissions.
Wong, Ka-ho
( University of Utah
, Salt Lake Cty
, Utah
, United States
)
Krothapalli, Neeharika
( Yale
, New Haven
, Connecticut
, United States
)
Littig, Lauren
( Yale
, New Haven
, Connecticut
, United States
)
Champagne, Alison
( Yale University
, Plantsville
, Connecticut
, United States
)
Majersik, Jennifer
( UNIVERSITY UTAH
, Salt Lake City
, Utah
, United States
)
Reddy, Vivek
( University of Utah
, Salt Lake City
, Utah
, United States
)
De Havenon, Adam
( Yale University
, New Haven
, Connecticut
, United States
)
Author Disclosures:
Ka-Ho Wong:DO have relevant financial relationships
;
Research Funding (PI or named investigator):TSF Foundation:Active (exists now)
; Research Funding (PI or named investigator):SRNA:Active (exists now)
| Neeharika Krothapalli:DO NOT have relevant financial relationships
| Lauren Littig:DO NOT have relevant financial relationships
| Alison Champagne:DO NOT have relevant financial relationships
| Jennifer Majersik:DO have relevant financial relationships
;
Researcher:NIH:Active (exists now)
; Independent Contractor:American Heart Association:Active (exists now)
| Vivek Reddy:No Answer
| Adam de Havenon:DO have relevant financial relationships
;
Research Funding (PI or named investigator):NIH/NINDS:Active (exists now)
; Researcher:UptoDate:Active (exists now)
; Individual Stocks/Stock Options:Certus:Active (exists now)
; Individual Stocks/Stock Options:TitinKM:Active (exists now)
; Consultant:Novo Nordisk:Active (exists now)
; Research Funding (PI or named investigator):AAN:Active (exists now)
Krothapalli Neeharika, Sansing Lauren, De Havenon Adam, Wong Ka-ho, Littig Lauren, Kim Yvonne, Smith Harper, Calvario Erick, Champagne Alison, Narula Reshma, Sheth Kevin